Anticancer agent 272

• Description :

  Anticancer agent 272 (Compound 2) is an anticancer agent. Anticancer agent 272 has significant anti-bladder cancer cell (T-24) activity (IC50: 2.81 μM) . Anticancer agent 272 consumes glutathione (GSH) through Fenton-like reaction, produces reactive oxygen species (ROS) and hydroxyl radicals (•OH), and induces apoptosis and ferroptosis. Anticancer agent 272 can enhance chemodynamic therapy (CDT) and promote tumor cell death through mitochondrial dysfunction and autophagy. Anticancer agent 272 has potential in the study of bladder cancer[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Ferroptosis; Reactive Oxygen Species (ROS)

• Related Pathways :

  Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Field of Research :

  Cancer

• Smiles :

  BrC1=CN=C(N2[N]([Cu+2]34([Cl-][Cu+2]5([Cl-])([Cl-]4)[N](N6C7=NC=C(C=[N]75)Br)=C(C=C6C(C)C)C(C)C)[Cl-])=C(C=C2C(C)C)C(C)C)[N]3=C1

• Molecular Formula :

  C26H34Br2Cl4Cu2N8

• Molecular Weight :

  887.31

• References & Citations :

  [1]Yang K, et al. Copper (II) Complexes of Pyrazolopyrimidine Derivatives as Anticancer Agents with Enhanced Chemodynamic Therapy through Bimodal Apoptosis and Ferroptosis. J Med Chem. 2025 Apr 10;68 (7) :7137-7152.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported